Current Environment: Production

Warning

Recall Alert

There is an antibacterial antibiotic recall. Read more

1 Boston Children's Hospital | Education

Undergraduate School

Biochemical Sciences

Harvard College

1997, Cambridge, MA

Medical School

Harvard Medical School

2001, Cambridge, MA

Internship

Pediatrics

Boston Children's Hospital

2002, Boston, MA

Residency

Pediatrics Boston Combined Residency Program (BCRP)

Boston, MA

Fellowship

Pediatric Pulmonology Boston Children's Hospital

2007, Boston, MA

Graduate School

Harvard School of Public Health

2007, Boston, MA

1 Boston Children's Hospital | Publications

  1. The effects of series elastic stiffness and cutaneous sensitivity on leg muscle reflex responses to unanticipated slips during walking. Exp Brain Res. 2025 May 20; 243(6):150. View The effects of series elastic stiffness and cutaneous sensitivity on leg muscle reflex responses to unanticipated slips during walking. Abstract

  2. Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model. Pediatr Pulmonol. 2025 May; 60(5):e71102. View Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model. Abstract

  3. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Apr 10. View Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study. Abstract

  4. The Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71042. View The Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis. Abstract

  5. Predictive control of musculotendon loads across fast and slow-twitch muscles in a simulated system with parallel actuation. Wearable Technol. 2025; 6:e8. View Predictive control of musculotendon loads across fast and slow-twitch muscles in a simulated system with parallel actuation. Abstract

  6. Acceptability of Telehealth Post-Pandemic Among Clinicians Across the United States Caring for People With Cystic Fibrosis. Pediatr Pulmonol. 2025 Feb; 60(2):e70000. View Acceptability of Telehealth Post-Pandemic Among Clinicians Across the United States Caring for People With Cystic Fibrosis. Abstract

  7. Male sexual and reproductive health in cystic fibrosis: A concept mapping study. J Cyst Fibros. 2025 Jan 28. View Male sexual and reproductive health in cystic fibrosis: A concept mapping study. Abstract

  8. Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States. NEJM Catal Innov Care Deliv. 2025 Feb; 6(2). View Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States. Abstract

  9. Electromyography-Informed Estimates of Joint Contact Forces Within the Lower Back and Knee Joints During a Diverse Set of Industry-Relevant Manual Lifting Tasks. J Appl Biomech. 2025 Apr 01; 41(2):151-160. View Electromyography-Informed Estimates of Joint Contact Forces Within the Lower Back and Knee Joints During a Diverse Set of Industry-Relevant Manual Lifting Tasks. Abstract

  10. "It's Like You're Feeding Your Child Twice": Barriers and Facilitators to Human Milk Feeding Children With Cystic Fibrosis. Pediatr Pulmonol. 2025 Jan; 60(1):e27497. View "It's Like You're Feeding Your Child Twice": Barriers and Facilitators to Human Milk Feeding Children With Cystic Fibrosis. Abstract

  11. Center of mass states render multijoint torques throughout standing balance recovery. J Neurophysiol. 2025 Jan 01; 133(1):206-221. View Center of mass states render multijoint torques throughout standing balance recovery. Abstract

  12. What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study. J Cyst Fibros. 2025 Jan; 24(1):187-192. View What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study. Abstract

  13. Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study. Contemp Clin Trials. 2025 Jan; 148:107752. View Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study. Abstract

  14. Reduced Achilles tendon stiffness in aging associates with higher metabolic cost of walking. J Appl Physiol (1985). 2024 Dec 01; 137(6):1541-1548. View Reduced Achilles tendon stiffness in aging associates with higher metabolic cost of walking. Abstract

  15. Plasma Microbial Cell-Free DNA Metagenomic Next-Generation Sequencing in People With Cystic Fibrosis. Pediatr Pulmonol. 2025 Jan; 60(1):e27380. View Plasma Microbial Cell-Free DNA Metagenomic Next-Generation Sequencing in People With Cystic Fibrosis. Abstract

  16. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515. View Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Abstract

  17. Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele. J Cyst Fibros. 2025 Jan; 24(1):135-141. View Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele. Abstract

  18. Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Front Nutr. 2024; 11:1441201. View Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Abstract

  19. Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. J Cyst Fibros. 2025 Jan; 24(1):91-97. View Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. Abstract

  20. Overview and Updates in Pediatric Pulmonary Medicine. Clin Chest Med. 2024 Sep; 45(3):xiii-xiv. View Overview and Updates in Pediatric Pulmonary Medicine. Abstract

  21. Center of mass states render multi-joint torques throughout standing balance recovery. bioRxiv. 2024 Aug 19. View Center of mass states render multi-joint torques throughout standing balance recovery. Abstract

  22. Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ). J Cyst Fibros. 2024 Nov; 23(6):1100-1105. View Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ). Abstract

  23. Cross-Cutting mHealth Behavior Change Techniques to Support Treatment Adherence and Self-Management of Complex Medical Conditions: Systematic Review. JMIR Mhealth Uhealth. 2024 May 01; 12:e49024. View Cross-Cutting mHealth Behavior Change Techniques to Support Treatment Adherence and Self-Management of Complex Medical Conditions: Systematic Review. Abstract

  24. Advances in Care and Outcomes for Children with Cystic Fibrosis. Clin Chest Med. 2024 Sep; 45(3):625-637. View Advances in Care and Outcomes for Children with Cystic Fibrosis. Abstract

  25. The effects of plantarflexor weakness and reduced tendon stiffness with aging on gait stability. PLoS One. 2024; 19(4):e0302021. View The effects of plantarflexor weakness and reduced tendon stiffness with aging on gait stability. Abstract

  26. A Data-Driven Approach to Estimate Human Center of Mass State During Perturbed Locomotion Using Simulated Wearable Sensors. Ann Biomed Eng. 2024 Aug; 52(8):2013-2023. View A Data-Driven Approach to Estimate Human Center of Mass State During Perturbed Locomotion Using Simulated Wearable Sensors. Abstract

  27. Dynamic Duo: Design and Validation of an Autonomous Frontal and Sagittal Actuating Hip Exoskeleton for Balance Modulation During Perturbed Locomotion. IEEE Robot Autom Lett. 2024 May; 9(5):3995-4002. View Dynamic Duo: Design and Validation of an Autonomous Frontal and Sagittal Actuating Hip Exoskeleton for Balance Modulation During Perturbed Locomotion. Abstract

  28. An emotional journey: caregiver experiences with gastrostomy tube decision-making for children with cystic fibrosis. J Cyst Fibros. 2024 Sep; 23(5):1000-1006. View An emotional journey: caregiver experiences with gastrostomy tube decision-making for children with cystic fibrosis. Abstract

  29. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol (Lausanne). 2024; 15:1293709. View Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Abstract

  30. Habitually wearing high heels may improve user walking economy in any footwear. J Appl Physiol (1985). 2024 Mar 01; 136(3):567-572. View Habitually wearing high heels may improve user walking economy in any footwear. Abstract

  31. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis. Clin Ther. 2024 02; 46(2):96-103. View Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis. Abstract

  32. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Diabetes Care. 2024 Jan 01; 47(1):101-108. View Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Abstract

  33. Reduced Achilles tendon stiffness in aging persists at matched activations and associates with higher metabolic cost of walking. bioRxiv. 2023 Nov 27. View Reduced Achilles tendon stiffness in aging persists at matched activations and associates with higher metabolic cost of walking. Abstract

  34. Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis. J Cyst Fibros. 2024 May; 23(3):417-423. View Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis. Abstract

  35. Simulations suggest walking with reduced propulsive force would not mitigate the energetic consequences of lower tendon stiffness. PLoS One. 2023; 18(10):e0293331. View Simulations suggest walking with reduced propulsive force would not mitigate the energetic consequences of lower tendon stiffness. Abstract

  36. Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. Exp Physiol. 2024 01; 109(1):148-158. View Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. Abstract

  37. Predictive Control of Peak Achilles Tendon Force in a Simulated System of the Human Ankle Joint with a Parallel Artificial Actuator During Hopping. IEEE Int Conf Rehabil Robot. 2023 09; 2023:1-6. View Predictive Control of Peak Achilles Tendon Force in a Simulated System of the Human Ankle Joint with a Parallel Artificial Actuator During Hopping. Abstract

  38. American Society of Biomechanics Journal of Biomechanics Award 2021: Exploring the Functional Boundaries and Metabolic Consequences of Triceps Surae Force-Length Relations during Walking. J Biomech. 2023 09; 158:111771. View American Society of Biomechanics Journal of Biomechanics Award 2021: Exploring the Functional Boundaries and Metabolic Consequences of Triceps Surae Force-Length Relations during Walking. Abstract

  39. Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. bioRxiv. 2023 May 09. View Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. Abstract

  40. Partners in research: The success with therapies research consortium and the CF community unite to improve self-management. J Cyst Fibros. 2023 09; 22(5):830-835. View Partners in research: The success with therapies research consortium and the CF community unite to improve self-management. Abstract

  41. The influence of induced gait asymmetry on joint reaction forces. J Biomech. 2023 05; 153:111581. View The influence of induced gait asymmetry on joint reaction forces. Abstract

  42. Perturbing the muscle work loop paradigm to unravel the neuromechanics of unsteady locomotion. J Exp Biol. 2023 04 01; 226(7). View Perturbing the muscle work loop paradigm to unravel the neuromechanics of unsteady locomotion. Abstract

  43. High deductible insurance plans impart economic burden for people with cystic fibrosis. Pediatr Pulmonol. 2023 06; 58(6):1798-1801. View High deductible insurance plans impart economic burden for people with cystic fibrosis. Abstract

  44. How many billions is enough? Prioritizing profits over patients with cystic fibrosis. Pediatr Pulmonol. 2023 05; 58(5):1595-1597. View How many billions is enough? Prioritizing profits over patients with cystic fibrosis. Abstract

  45. Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. J Cyst Fibros. 2023 May; 22(3):464-470. View Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. Abstract

  46. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS. J Cyst Fibros. 2023 May; 22(3):402-406. View EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS. Abstract

  47. Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis. J Cyst Fibros. 2023 May; 22(3):431-435. View Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis. Abstract

  48. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023 04; 11(4):329-340. View Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Abstract

  49. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Pulm Ther. 2022 Dec; 8(4):385-395. View Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Abstract

  50. Sexual and reproductive health experiences and care of adult women with cystic fibrosis. J Cyst Fibros. 2023 03; 22(2):223-233. View Sexual and reproductive health experiences and care of adult women with cystic fibrosis. Abstract

  51. Real-world feasibility of short-term, unsupervised home spirometry in CF. Pediatr Pulmonol. 2022 12; 57(12):3129-3135. View Real-world feasibility of short-term, unsupervised home spirometry in CF. Abstract

  52. Eating disorders in adolescents and young adults with cystic fibrosis. Pediatr Pulmonol. 2022 11; 57(11):2791-2797. View Eating disorders in adolescents and young adults with cystic fibrosis. Abstract

  53. Author Reply to: Empowering Without Misinforming Adolescents and Young Adults with Cystic Fibrosis. Comment on "Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study". JMIR Pediatr Parent. 2022 May 25; 5(2):e39450. View Author Reply to: Empowering Without Misinforming Adolescents and Young Adults with Cystic Fibrosis. Comment on "Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study". Abstract

  54. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1444-e1454. View Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. Abstract

  55. Understanding the Intersection between Gender Transition and Health Outcomes in Cystic Fibrosis. Ann Am Thorac Soc. 2022 03; 19(3):504-506. View Understanding the Intersection between Gender Transition and Health Outcomes in Cystic Fibrosis. Abstract

  56. A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children = 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. J Cyst Fibros. 2022 07; 21(4):675-683. View A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children = 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Abstract

  57. Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies-A qualitative study. J Cyst Fibros. 2022 07; 21(4):657-661. View Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies-A qualitative study. Abstract

  58. Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis. J Patient Exp. 2022; 9:23743735221077527. View Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis. Abstract

  59. The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Nutrients. 2022 Jan 12; 14(2). View The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Abstract

  60. Exploring provider attitudes and perspectives related to men's health in cystic fibrosis. J Cyst Fibros. 2022 07; 21(4):652-656. View Exploring provider attitudes and perspectives related to men's health in cystic fibrosis. Abstract

  61. Trajectories of the Transition Readiness Assessment Questionnaire Among Youth With Inflammatory Bowel Disease. J Clin Gastroenterol. 2022 10 01; 56(9):805-809. View Trajectories of the Transition Readiness Assessment Questionnaire Among Youth With Inflammatory Bowel Disease. Abstract

  62. Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. J Cyst Fibros. 2021 12; 20 Suppl 3:16-20. View Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. Abstract

  63. Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. J Cyst Fibros. 2021 12; 20 Suppl 3:41-46. View Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. Abstract

  64. Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros. 2021 12; 20 Suppl 3:57-63. View Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. Abstract

  65. Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. J Cyst Fibros. 2021 12; 20 Suppl 3:9-13. View Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. Abstract

  66. Prevalence, variability, and predictors of sinus surgery in pediatric patients with cystic fibrosis. Pediatr Pulmonol. 2021 12; 56(12):4029-4038. View Prevalence, variability, and predictors of sinus surgery in pediatric patients with cystic fibrosis. Abstract

  67. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022 03; 21(2):258-263. View The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. Abstract

  68. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592. View Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Abstract

  69. Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study. JMIR Pediatr Parent. 2021 Aug 16; 4(3):e25014. View Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study. Abstract

  70. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Ann Am Thorac Soc. 2021 08; 18(8):1397-1405. View Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Abstract

  71. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103. View Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Abstract

  72. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261. View The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. Abstract

  73. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 03 01; 203(5):585-593. View Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Abstract

  74. Rapid Implementation of Telehealth Services in a Pediatric Pulmonary Clinic During COVID-19. Pediatrics. 2021 07; 148(1). View Rapid Implementation of Telehealth Services in a Pediatric Pulmonary Clinic During COVID-19. Abstract

  75. An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Pediatr Pulmonol. 2021 05; 56(5):928-938. View An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Abstract

  76. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746. View Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Abstract

  77. Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery. Laryngoscope. 2021 09; 131(9):1930-1938. View Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery. Abstract

  78. Tribulations and (clinical) trials in cystic fibrosis. J Cyst Fibros. 2021 03; 20(2):188-190. View Tribulations and (clinical) trials in cystic fibrosis. Abstract

  79. Transition Readiness Not Associated With Measures of Health in Youth With IBD. Inflamm Bowel Dis. 2021 01 01; 27(1):49-57. View Transition Readiness Not Associated With Measures of Health in Youth With IBD. Abstract

  80. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123. View Men's health in the modern era of cystic fibrosis. Abstract

  81. Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. J Endocr Soc. 2021 Jan 01; 5(1):bvaa165. View Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. Abstract

  82. Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros. 2021 01; 20(1):120-126. View Decreased survival in cystic fibrosis patients with a positive screen for depression. Abstract

  83. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. Pediatr Pulmonol. 2020 11; 55(11):2983-2989. View Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. Abstract

  84. Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. J Pediatr. 2019 12; 215:164-171.e2. View Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. Abstract

  85. Male gender and unemployment are associated with lower levels of perceived social support in adults with cystic fibrosis. J Psychosom Res. 2019 12; 127:109858. View Male gender and unemployment are associated with lower levels of perceived social support in adults with cystic fibrosis. Abstract

  86. Medical Deferred Action - Living on Borrowed Time. N Engl J Med. 2019 Oct 24; 381(17):1601-1603. View Medical Deferred Action - Living on Borrowed Time. Abstract

  87. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414. View Predictors of pulmonary exacerbation treatment in cystic fibrosis. Abstract

  88. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713. View A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. Abstract

  89. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2020 01; 19(1):68-79. View Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. Abstract

  90. Chronic rhino-sinusitis treatment in children with cystic fibrosis: A cross-sectional survey of pediatric pulmonologists and otolaryngologists. Int J Pediatr Otorhinolaryngol. 2019 Sep; 124:139-142. View Chronic rhino-sinusitis treatment in children with cystic fibrosis: A cross-sectional survey of pediatric pulmonologists and otolaryngologists. Abstract

  91. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB). J Cyst Fibros. 2019 11; 18(6):838-843. View An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB). Abstract

  92. Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement. Patient. 2019 04; 12(2):267-276. View Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement. Abstract

  93. Linkage of the CF foundation patient registry with the pediatric health information system database. Pediatr Pulmonol. 2019 06; 54(6):721-728. View Linkage of the CF foundation patient registry with the pediatric health information system database. Abstract

  94. Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):671-676. View Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. Abstract

  95. Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. J Cyst Fibros. 2019 07; 18(4):572-576. View Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. Abstract

  96. Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Health Aff (Millwood). 2019 02; 38(2):328. View Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Abstract

  97. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019 04; 7(4):325-335. View Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Abstract

  98. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018 12; 53(12):1611-1618. View Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Abstract

  99. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med. 2018 10 15; 198(8):1055-1063. View Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Abstract

  100. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018 Oct; 2(5):334-342. View Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. Abstract

  101. Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18?months following approval in the United States. J Cyst Fibros. 2018 11; 17(6):742-746. View Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18?months following approval in the United States. Abstract

  102. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Abstract

  103. The burden of cystic fibrosis in the Medicaid population. Clinicoecon Outcomes Res. 2018; 10:423-431. View The burden of cystic fibrosis in the Medicaid population. Abstract

  104. Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Pediatr Pulmonol. 2018 11; 53(S3):S86-S92. View Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Abstract

  105. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018 08; 73(8):731-740. View Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Abstract

  106. Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. Health Aff (Millwood). 2018 05; 37(5):773-779. View Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. Abstract

  107. Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education. Pediatr Pulmonol. 2018 08; 53(8):1027-1034. View Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education. Abstract

  108. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2018 04; 15(4):485-493. View Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Abstract

  109. Cystic fibrosis patient registries: A valuable source for clinical research. J Cyst Fibros. 2018 07; 17(4):433-440. View Cystic fibrosis patient registries: A valuable source for clinical research. Abstract

  110. Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis. Pediatr Pulmonol. 2018 06; 53(6):720-727. View Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis. Abstract

  111. Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Ann Am Thorac Soc. 2018 02; 15(2):234-240. View Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Abstract

  112. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J Cyst Fibros. 2018 05; 17(3):e25-e31. View Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Abstract

  113. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. J Cyst Fibros. 2018 07; 17(4):503-510. View Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Abstract

  114. Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis. J Cyst Fibros. 2018 01; 17(1):64-70. View Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis. Abstract

  115. Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis. Psychosomatics. 2018 Mar - Apr; 59(2):158-168. View Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis. Abstract

  116. Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol. 2017 10; 52(10):1276-1282. View Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Abstract

  117. Early Lung Function Decline in Cystic Fibrosis. Can Registry Data Explain Divergent Phenotypes? Am J Respir Crit Care Med. 2017 08 15; 196(4):407-409. View Early Lung Function Decline in Cystic Fibrosis. Can Registry Data Explain Divergent Phenotypes? Abstract

  118. Pediatric lung transplantation and end of life care in cystic fibrosis: Barriers and successful strategies. Pediatr Pulmonol. 2017 Nov; 52(S48):S61-S68. View Pediatric lung transplantation and end of life care in cystic fibrosis: Barriers and successful strategies. Abstract

  119. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. J Cyst Fibros. 2018 01; 17(1):57-63. View Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. Abstract

  120. Preparation for Transition to Adult Care Among Medicaid-Insured Adolescents. Pediatrics. 2017 Jul; 140(1). View Preparation for Transition to Adult Care Among Medicaid-Insured Adolescents. Abstract

  121. Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. Am J Respir Crit Care Med. 2017 06 15; 195(12):1673-1676. View Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. Abstract

  122. Impact of an Individual Mandate and Other Health Reforms on Dependent Coverage for Adolescents and Young Adults. Health Serv Res. 2018 06; 53(3):1581-1599. View Impact of an Individual Mandate and Other Health Reforms on Dependent Coverage for Adolescents and Young Adults. Abstract

  123. Utilization of a patient-centered asthma passport tool in a subspecialty clinic. J Asthma. 2018 02; 55(2):180-187. View Utilization of a patient-centered asthma passport tool in a subspecialty clinic. Abstract

  124. Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients. Otolaryngol Head Neck Surg. 2017 08; 157(2):302-308. View Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients. Abstract

  125. Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. J Pediatr Gastroenterol Nutr. 2017 04; 64(4):505-511. View Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. Abstract

  126. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. J Cyst Fibros. 2018 01; 17(1):71-77. View The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. Abstract

  127. Adherence and Recursive Perception Among Young Adults with Cystic Fibrosis. Anthropol Med. 2017 Apr; 24(1):65-80. View Adherence and Recursive Perception Among Young Adults with Cystic Fibrosis. Abstract

  128. Counterpoint: Too little care or too little collaboration: Approaches to treatment refusal in CF. J Cyst Fibros. 2017 03; 16(2):304-305. View Counterpoint: Too little care or too little collaboration: Approaches to treatment refusal in CF. Abstract

  129. Provider Attitudes and Practices toward Sexual and Reproductive Health Care for Young Women with Cystic Fibrosis. J Pediatr Adolesc Gynecol. 2017 Oct; 30(5):546-552. View Provider Attitudes and Practices toward Sexual and Reproductive Health Care for Young Women with Cystic Fibrosis. Abstract

  130. Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared? Am J Respir Crit Care Med. 2017 02 01; 195(3):405-406. View Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared? Abstract

  131. Obesity and Airway Dysanapsis in Children with and without Asthma. Am J Respir Crit Care Med. 2017 Feb 01; 195(3):314-323. View Obesity and Airway Dysanapsis in Children with and without Asthma. Abstract

  132. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017 02; 5(2):107-118. View Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Abstract

  133. Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Patient Prefer Adherence. 2016; 10:2163-2169. View Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Abstract

  134. Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther. 2016; 7:117-124. View Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Abstract

  135. Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. Pediatr Blood Cancer. 2017 02; 64(2):346-352. View Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. Abstract

  136. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. J Med Econ. 2016 Sep; 19(9):845-51. View Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Abstract

  137. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Abstract

  138. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016 Feb; 4(2):107-15. View Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Abstract

  139. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. Abstract

  140. CF RISE: Implementing a Clinic-Based Transition Program. Pediatr Allergy Immunol Pulmonol. 2015 Dec; 28(4):250-254. View CF RISE: Implementing a Clinic-Based Transition Program. Abstract

  141. Tackling the increasing complexity of CF care. Pediatr Pulmonol. 2015 Oct; 50 Suppl 40:S74-9. View Tackling the increasing complexity of CF care. Abstract

  142. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015 Oct 01; 192(7):836-42. View Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Abstract

  143. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1. View Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. Abstract

  144. Development and Validation of the Adolescent Assessment of Preparation for Transition: A Novel Patient Experience Measure. J Adolesc Health. 2015 Sep; 57(3):282-7. View Development and Validation of the Adolescent Assessment of Preparation for Transition: A Novel Patient Experience Measure. Abstract

  145. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Ann Am Thorac Soc. 2015 Aug; 12(8):1146-52. View Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Abstract

  146. A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients. J Cyst Fibros. 2016 Mar; 15(2):234-41. View A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients. Abstract

  147. Self-Management and Transition Readiness Assessment: Concurrent, Predictive and Discriminant Validation of the STARx Questionnaire. J Pediatr Nurs. 2015 Sep-Oct; 30(5):668-76. View Self-Management and Transition Readiness Assessment: Concurrent, Predictive and Discriminant Validation of the STARx Questionnaire. Abstract

  148. Predictors of timing of transfer from pediatric- to adult-focused primary care. JAMA Pediatr. 2015 Jun; 169(6):e150951. View Predictors of timing of transfer from pediatric- to adult-focused primary care. Abstract

  149. Similar performance of Brasfield and Wisconsin scoring systems in young children with cystic fibrosis. Pediatr Radiol. 2015 Oct; 45(11):1624-8. View Similar performance of Brasfield and Wisconsin scoring systems in young children with cystic fibrosis. Abstract

  150. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):777-83. View Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. Abstract

  151. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. J Cyst Fibros. 2016 Jan; 15(1):90-5. View Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. Abstract

  152. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Pediatr Pulmonol. 2015 May; 50(5):431-40. View Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Abstract

  153. Ready, set, stop: mismatch between self-care beliefs, transition readiness skills, and transition planning among adolescents, young adults, and parents. Clin Pediatr (Phila). 2014 Oct; 53(11):1062-8. View Ready, set, stop: mismatch between self-care beliefs, transition readiness skills, and transition planning among adolescents, young adults, and parents. Abstract

  154. The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. Acad Pediatr. 2014 Jul-Aug; 14(4):415-22. View The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. Abstract

  155. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. Abstract

  156. Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis. Pediatr Pulmonol. 2015 Mar; 50(3):231-235. View Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis. Abstract

  157. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol. 2015 Feb; 50(2):127-36. View Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Abstract

  158. Transition care: future directions in education, health policy, and outcomes research. Acad Pediatr. 2014 Mar-Apr; 14(2):120-7. View Transition care: future directions in education, health policy, and outcomes research. Abstract

  159. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc. 2014 Feb; 11(2):205-10. View Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Abstract

  160. Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective. J Pediatr Rehabil Med. 2014; 7(1):43-51. View Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective. Abstract

  161. Brasfield and Wisconsin scoring systems have equal value as outcome assessment tools of cystic fibrosis lung disease. Pediatr Radiol. 2014 May; 44(5):529-34. View Brasfield and Wisconsin scoring systems have equal value as outcome assessment tools of cystic fibrosis lung disease. Abstract

  162. Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest. 2013 Sep; 144(3):981-989. View Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Abstract

  163. Claim-based analyses of inhaled corticosteroid refill rates for asthma: who's kidding whom? Ann Am Thorac Soc. 2013 Apr; 10(2):149-50. View Claim-based analyses of inhaled corticosteroid refill rates for asthma: who's kidding whom? Abstract

  164. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros. 2013 Sep; 12(5):461-7. View Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. Abstract

  165. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol. 2013 Oct; 48(10):954-61. View A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Abstract

  166. Referral patterns and perceived barriers to adult congenital heart disease care: results of a survey of U.S. pediatric cardiologists. J Am Coll Cardiol. 2012 Dec 11; 60(23):2411-8. View Referral patterns and perceived barriers to adult congenital heart disease care: results of a survey of U.S. pediatric cardiologists. Abstract

  167. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012 Jun; 47(6):523-33. View Managing treatment complexity in cystic fibrosis: challenges and opportunities. Abstract

  168. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res. 2012 Sep; 21(7):1279-90. View Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Abstract

  169. The impact of reflux burden on Pseudomonas positivity in children with cystic fibrosis. Pediatr Pulmonol. 2012 Jun; 47(6):582-7. View The impact of reflux burden on Pseudomonas positivity in children with cystic fibrosis. Abstract

  170. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res. 2012 Sep; 21(7):1267-78. View Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Abstract

  171. Physician practices for communicating with patients with cystic fibrosis about the use of noninvasive and invasive mechanical ventilation. Chest. 2012 Apr; 141(4):1010-1017. View Physician practices for communicating with patients with cystic fibrosis about the use of noninvasive and invasive mechanical ventilation. Abstract

  172. Assessment of current strategies for weaning premature infants from supplemental oxygen in the outpatient setting. Adv Neonatal Care. 2011 Oct; 11(5):349-56. View Assessment of current strategies for weaning premature infants from supplemental oxygen in the outpatient setting. Abstract

  173. Receipt of health care transition counseling in the national survey of adult transition and health. Pediatrics. 2011 Sep; 128(3):e521-9. View Receipt of health care transition counseling in the national survey of adult transition and health. Abstract

  174. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012 Jan; 47(1):44-52. View Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Abstract

  175. Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr (Phila). 2011 Feb; 50(2):133-9. View Tree nut allergy, egg allergy, and asthma in children. Abstract

  176. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol. 2011 Jan; 46(1):36-44. View Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Abstract

  177. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View Employment experiences among adolescents and young adults with cystic fibrosis. Abstract

  178. Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis. J Psychosom Res. 2011 Feb; 70(2):161-7. View Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis. Abstract

  179. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. J Asthma. 2010 Jun; 47(5):574-80. View Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. Abstract

  180. Cystic fibrosis and transition to adult medical care. Pediatrics. 2010 Mar; 125(3):566-73. View Cystic fibrosis and transition to adult medical care. Abstract

  181. Asthma care quality for children with minority-serving providers. Arch Pediatr Adolesc Med. 2010 Jan; 164(1):38-45. View Asthma care quality for children with minority-serving providers. Abstract

  182. Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study. Ann Allergy Asthma Immunol. 2010 Jan; 104(1):30-5. View Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study. Abstract

  183. Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire. J Pediatr Psychol. 2011 Mar; 36(2):160-71. View Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire. Abstract

  184. Travel patterns to school among children with asthma. Clin Pediatr (Phila). 2009 Jul; 48(6):632-40. View Travel patterns to school among children with asthma. Abstract

  185. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2009 Apr 15; 179(8):734-5; author reply 735. View The impact of MRSA on lung function in patients with cystic fibrosis. Abstract

  186. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008 Nov; 43(11):1117-1123. View The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Abstract

  187. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009 Mar; 8(2):91-6. View High treatment burden in adults with cystic fibrosis: challenges to disease self-management. Abstract

  188. Advance care planning in adults with cystic fibrosis. J Palliat Med. 2008 Oct; 11(8):1135-41. View Advance care planning in adults with cystic fibrosis. Abstract

  189. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur Respir J. 2008 Jun; 31(6):1285-91. View Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Abstract

  190. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage. 2008 Apr; 35(4):372-80. View Self-reported physical and psychological symptom burden in adults with cystic fibrosis. Abstract

  191. Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? Clin Pediatr (Phila). 2008 Jun; 47(5):446-51. View Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? Abstract

  192. Bronchoscopy findings in children and young adults with tracheostomy due to congenital anomalies and neurological impairment. J Pediatr Rehabil Med. 2008; 1(2):137-43. View Bronchoscopy findings in children and young adults with tracheostomy due to congenital anomalies and neurological impairment. Abstract

  193. Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol. 2007 Dec; 37(12):1278-82. View Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Abstract

  194. Self-reported involvement of family members in the care of adults with CF. J Cyst Fibros. 2008 Mar; 7(2):95-101. View Self-reported involvement of family members in the care of adults with CF. Abstract

  195. Adults with cystic fibrosis report important and unmet needs for disease information. J Cyst Fibros. 2007 Nov 30; 6(6):411-6. View Adults with cystic fibrosis report important and unmet needs for disease information. Abstract

  196. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol. 1997 Oct 15; 159(8):3723-30. View Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. Abstract

1 Boston Children's Hospital | Education

Undergraduate School

Tufts University

2000, Boston, MA

Medical School

Tufts University School of Medicine

2005, Boston, MA

Internship

Floating Hospital for Children Tufts Medical Center

2006, Boston, MA

Residency

Floating Hospital for Children Tufts Medical Center

2008, Boston, MA

Fellowship

Pediatric Nephrology

Boston Children's Hospital

2011, Boston, MA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Undergraduate School

Villanova University

1984, Philadelphia, PA

Medical School

Johns Hopkins Medical School

1988, Baltimore, MD

Residency

Johns Hopkins Medical School

1991, Baltimore, MD

Fellowship

Boston Children's Hospital

1994, Boston, MA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Medical School

University of Pennsylvania School of Medicine

1986, Philadelphia, PA

Internship

New England Deaconess Hospital

1987, Boston, MA

Residency

Massachusetts General Hospital

1992, Boston, MA

Fellowship

Boston Children's Hospital

1994, Boston, MA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Medical School

Harvard Medical School

1997, Boston, MA

Internship

Boston Combined Residency Program (BCRP)

1998, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2000, Boston, MA

Residency

Chief Residency

Boston Children's Hospital

2001, Boston, MA

Fellowship

Pediatric Infectious Diseases

Boston Children's Hospital

2004, Boston, MA

Graduate School

MPH

Harvard School of Public Health

2004, Boston, MA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Medical School

University of Miami School of Medicine

1999, Miami, FL

Residency

Pediatrics

University of Miami School of Medicine/Jackson Memorial Medical Center

2002, Miami, FL

Residency

Pediatrics

University of Miami School of Medicine/Jackson Memorial Medical Center

2003, Miami, FL

Fellowship

Pediatric Infectious Diseases and Immunology

University of Miami School of Medicine/Jackson Memorial Medical Center

2005, Miami, FL

Graduate School

MPH

Harvard School of Public Health

2014, Boston, MA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Medical School

MBBS

Maulana Azad Medical College, University of Delhi

1984, New Delhi, India

Medical School

MD

Maulana Azad Medical College, University of Delhi

1989, New Delhi, India

Residency

Pediatrics

Maulana Azad Medical College & Associated LNJP Hospital

1990, New Delhi, India

Residency

Pediatrics

Children's Hospital of Michigan

1993, Detroit, MI

Fellowship

Pediatric Cardiology

Children's Hospital of Michigan

1996, Detroit, MI

Fellowship

Cardiac PET, Cardiac Transplant

Children's Hospital of Michigan

1997, Detroit, MI

Graduate School

MSc, Clinical Research Design & Statistical Analysis

University of Michigan

2005, Ann Arbor, MI

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Internship

Pediatrics

Boston Children's Hospital

1994, Boston, MA

Medical School

University of Massachusetts

1993, Worcester, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

1996, Boston, MA

Undergraduate School

University of Pennsylvania

1989, Philadelphia, PA

Fellowship

Pediatric Hematology -Oncology

Children's Hospital of Philadelphia

2000, Philadelphia, PA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Medical School

New York University School of Medicine

1990, New York, NY

Residency

Hospital of the University of Pennsylvania

1994, Philadelphia, PA

Fellowship

Hospital of the University of Pennsylvania

1996, Philadelphia, PA

1 Boston Children's Hospital | Publications

1 Boston Children's Hospital | Education

Undergraduate School

Tufts University

Boston, MA

Graduate School

Albert Einstein College of Medicine

New York, NY

Medical School

Albert Einstein College of Medicine

New York, NY

Residency

Brigham and Women's Hospital

Boston, MA

Fellowship

Massachusetts General Hospital/Harvard Medical School

Boston, MA

1 Boston Children's Hospital | Publications

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services